Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies

References

• Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7
   PubMed Web of Science ®Google Scholar
• Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995;332:581-8
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-19
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
   PubMed Web of Science ®Google Scholar
• Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6
   PubMed Web of Science ®Google Scholar
• Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-3
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Derm Treat 2005;16:319-23
   PubMed Web of Science ®Google Scholar
• Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-5
   Google Scholar
• Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003;4:833-42
   PubMed Web of Science ®Google Scholar
• Morse RM, Perry HO, Hurt RD. Alcoholism and psoriasis. Alcohol Clin Exp Res 1985;9:396-9
   PubMed Web of Science ®Google Scholar
• Bø K, Thoresen M, Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008;216:40-5
   PubMed Web of Science ®Google Scholar
• Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses’ Health Study II. Am J Med 2007;120:953-9
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15
   PubMed Web of Science ®Google Scholar
• McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469-75
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8
   PubMed Web of Science ®Google Scholar
• Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107-16
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
   PubMed Web of Science ®Google Scholar
• Costanzo A, Mazzotta A, Papoutsaki M, et al. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005;152:187-9
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2:862-71
   PubMed Web of Science ®Google Scholar
• Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-72
   PubMed Web of Science ®Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007;46:1824-7
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Eur Acad Dermatol Venereol 2008;22:341-4
   PubMed Web of Science ®Google Scholar
• Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005;64:1137-40
   PubMed Web of Science ®Google Scholar
• Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005;90:3510-16
   PubMed Web of Science ®Google Scholar
• Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290-5
   PubMed Web of Science ®Google Scholar
• Psocare report 2007, 30th October 2008. http://www.psocare.it/cms/system/files/u3/PSOCARE-2report_m.pdf
   Google Scholar
• Livio F, Ivanyuk A, Biollaz J. Pharmacovigilance and teratogen 2008. Rev Med Suisse 2009;5:130-4
   PubMedGoogle Scholar
• Prignano F, Buggiani G, Lotti T. Efalizumab in the treatment of psoriasis: when comorbidity is an issue. Dermatol Ther 2008; 21:s25-9
   PubMed Web of Science ®Google Scholar
• Girolomoni Gisondi P. Psoriasis and metabolic comorbidities: the importance of well-designed prospective studies. Commentary. Dermatology 2008;217:222-4
   PubMed Web of Science ®Google Scholar